What is it about?
It is not so easy practice to prescribe nucleoside analogs in the countries where measurement of HBV markers including HBV DNA are not available.
Featured Image
Why is it important?
Introduction of tenofovir that no emergence of HBV mutations is reported as long as 8 years in western countries might be acceptable in Nepal, where measurements of HBV genotypes, HBV viral loads and HBV mutations are not available.
Perspectives
We need to further consider the introduction of HBsAg quantification methods in the developing countries, in order to decrease the incidence of HBV-related hepatocellular carcinoma as much as possible and to satisfy the request of WHO Agenda 2030.
Dr NAOHIKO MASAKI
National Center for Global Health and Medicine
Read the Original
This page is a summary of: Use of nucleoside analogs in patients with chronic hepatitis B in Nepal: A prospective cohort study in a single hospital, Hepatology Research, February 2015, Wiley,
DOI: 10.1111/hepr.12482.
You can read the full text:
Contributors
The following have contributed to this page
